Mission Street is a specialist investor, developer and operator for the science and innovation sector. The company’s science and innovation portfolio of over 1 million sq ft (93,000 sq m) extends to Cambridge, Oxford and Bristol. Mission Street have also been active as development managers
(for example, on Sycamore House in Stevenage, which featured in the 30 September 2022 edition of Life Sciences Real Estate).
We caught up with founder and CEO Artem Korolev in his office in London’s West End.
Phase 2 of new science hub for Central Oxford (source: Mission Street)
How could the life sciences and real estate sectors work better together?
Some of the major challenges at the moment are that the real estate and sciences sectors work at different paces. Growth of knowledge intensive businesses is often extremely rapid, whilst the development cycle usually
takes several years – so we need to take a view on future evolution
of our ecosystems. Secondly, real estate can often become an echo chamber driven by pre-conceived notions of best practice which are siloed from the wants of the ultimate customers.
Read the full story
Sign up
now to read the full story and get access to all posts for
paying subscribers only.
Rob Beacroft believes life sciences real estate will not remain niche but will become an increasingly important part of investors’ allocations to alternatives.
